Oramed Pharmaceuticals (ORMP) Long-Term Debt Issuances (2023 - 2025)
Oramed Pharmaceuticals' (ORMP) quarterly Long-Term Debt Issuances came in at $65.5 million in Q2 2025, up 114.33% YoY from $30.6 million in Q2 2024, and down 5.38% on a QoQ basis from $69.2 million in Q1 2025.
Oramed Pharmaceuticals (ORMP) Long-Term Debt Issuances (2023 - 2025) Analysis & Trends
Oramed Pharmaceuticals (ORMP) has 3 years of Long-Term Debt Issuances data on file, last reported at $65.5 million in Q2 2025.
- Quarterly Long-Term Debt Issuances rose 114.33% year-over-year to $65.5 million in Q2 2025, while the trailing twelve-month figure through Dec 2025 was $134.7 million (up 171.8% YoY) and the FY2025 annual result came in at $69.2 million, up 39.66% from the prior year.
- Long-Term Debt Issuances declined to $65.5 million in Q2 2025, from $69.2 million in the prior quarter.
- In the past five years, Long-Term Debt Issuances ranged from a high of $74.6 million in Q4 2023 to a low of $19.0 million in Q1 2024.
- A 3-year average of $51.8 million and a median of $65.5 million in 2025 frame the typical range for Long-Term Debt Issuances.
- The widest YoY moves for Long-Term Debt Issuances: up 264.21% in 2025, down 114.33% in 2025.
- Tracing ORMP's Long-Term Debt Issuances over 3 years: stood at $74.6 million in 2023, then tumbled by 59.02% to $30.6 million in 2024, then surged by 114.33% to $65.5 million in 2025.
- The last three Long-Term Debt Issuances figures came in at $65.5 million (Q2 2025), $69.2 million (Q1 2025), and $30.6 million (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Oramed Pharmaceuticals | 197.61 Mn | 197.61 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 65.48 Mn |
| Jun 30, 2025 | 65.48 Mn |
| Mar 31, 2025 | 69.20 Mn |
| Mar 31, 2025 | 69.20 Mn |
| Jun 30, 2024 | 30.55 Mn |
| Jun 30, 2024 | 30.55 Mn |
| Mar 31, 2024 | 19.00 Mn |
| Mar 31, 2024 | 19.00 Mn |
| Dec 31, 2023 | 74.55 Mn |
| Dec 31, 2023 | 74.55 Mn |